...
首页> 外文期刊>Cytotherapy >Sub-confluent culture of human mesenchymal stromal cells on biodegradable polycaprolactone microcarriers enhances bone healing of rat calvarial defect
【24h】

Sub-confluent culture of human mesenchymal stromal cells on biodegradable polycaprolactone microcarriers enhances bone healing of rat calvarial defect

机译:生物降解的聚己内酯微载体对人间充质基质细胞的亚汇合培养增强了大鼠颅骨缺损的骨愈合

获取原文
获取原文并翻译 | 示例

摘要

In the current emerging trend of using human mesenchymal stromal cell (MSCs) for cell therapy, large quantities of cells are needed for clinical testing. Current methods of culturing cells, using tissue culture flasks or cell multilayer vessels, are proving to be ineffective in terms of cost, space and manpower. Therefore, alternatives such as large-scale industrialized production of MSCs in stirred tank bioreactors using microcarriers (MCs) are needed. Moreover, the development of biodegradable MCs for MSC expansion can streamline the bioprocess by eliminating the need for enzymatic cell harvesting and scaffold seeding for bone-healing therapies. Our previous studies described a process of making regulated density (1.06 g/cm(3)) porous polycaprolactone biodegradable MCs Light Polycarprolactone (LPCL) (MCs), which were used for expanding MSCs from various sources in stirred suspension culture. Here, we use human early MSCs (heMSCs) expanded on LPCL MCs for evaluation of their osteogenic differentiation potential in vitro as well as their use in vivo calvarial defect treatment in a rat model. In summary, (i) in vitro data show that LPCL MCs can be used to efficiently expand heMSCs in stirred cultures while maintaining surface marker expression; (ii) LPCL MCs can be used as scaffolds for cell transfer for transplantation in vivo; (iii) 50% subconfluency, mid-logarithmic phase, on LPCLMCs (50% confluent) exhibited higher secretion levels of six cytokines (interleukin [IL]-6, IL-8, Vascular endothelial growth factor (VEGF), Monocyte Chemoattractant Protein-1 (MCP-1), growth-regulated oncogene-alpha (GRO-alpha) and stromal cell-derived factor-1 alpha (SDF-1 alpha)) as compared with 100% confluent, stationary phase cultures (100% confluent); (iv) these 50% confluent cultures demonstrated better in vitro osteogenic differentiation capacity as compared with 100% confluent cultures (higher levels of calcium deposition and at earlier stage); the improved bone differentiation
机译:在目前使用人间充质基质细胞(MSCs)用于细胞疗法的新出现趋势,临床测试需要大量的细胞。使用组织培养烧瓶或细胞多层血管的培养细胞的目前方法在成本,空间和人力方面证明是无效的。因此,需要使用使用微载体(MCS)的搅拌釜生物反应器中的大规模工业化生产的替代品如大规模的工业化生产。此外,用于MSC扩展的可生物降解MCS的发展可以通过消除对骨干疗法的酶促细胞收获和支架播种来流动生物过程。我们以前的研究描述了制备调节密度(1.06g / cm(3))多孔多己内酯可生物降解的MCS光聚羰丙酮(LPCL)(MCS)的过程,其用于扩增来自搅拌悬浮培养的各种来源的MSCs。在这里,我们使用人类早期MSC(HEMSCs)在LPCL MC上扩展,以评估其体外的骨质发生分化潜力,以及它们在大鼠模型中的体内颅骨缺陷治疗。总之,(i)体外数据表明,LPCL MCS可用于在保持表面标记表达的同时有效地扩张搅拌培养物中的HEMSC; (ii)LPCL MCS可用作体内移植的细胞转移的支架; (iii)50%的亚次血换,LPCLMC(50%汇合)的中数阶段表现出较高的分泌水平的六种细胞因子(白细胞介素[IL] -6,IL-8,血管内皮生长因子(VEGF),单核细胞化学毒性蛋白 - 与100%汇合,固定相培养物(100%汇合)相比,1(MCP-1),生长调节的癌烯-α(GRO-α)和基质电池衍生因子-1α(SDF-1α); (iv)与100%汇合培养物(较高水平的钙沉积和早期阶段更高水平)相比,这些50%汇合培养物的体外骨质化分化能力更好;改善的骨分化

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号